184 related articles for article (PubMed ID: 11679109)
1. Continuous flow peritoneal dialysis: solution formulation and biocompatibility.
Passlick-Deetjen J; Lage C; Jörres A
Semin Dial; 2001; 14(5):384-7. PubMed ID: 11679109
[TBL] [Abstract][Full Text] [Related]
2. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
4. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products.
Mortier S; De Vriese AS; Van de Voorde J; Schaub TP; Passlick-Deetjen J; Lameire NH
J Am Soc Nephrol; 2002 Feb; 13(2):480-489. PubMed ID: 11805178
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
7. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
8. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
9. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
10. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.
Haas S; Schmitt CP; Arbeiter K; Bonzel KE; Fischbach M; John U; Pieper AK; Schaub TP; Passlick-Deetjen J; Mehls O; Schaefer F
J Am Soc Nephrol; 2003 Oct; 14(10):2632-8. PubMed ID: 14514742
[TBL] [Abstract][Full Text] [Related]
11. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function.
Jörres A; Bender TO; Finn A; Witowski J; Fröhlich S; Gahl GM; Frei U; Keck H; Passlick-Deetjen J
Kidney Int; 1998 Dec; 54(6):2184-93. PubMed ID: 9853285
[TBL] [Abstract][Full Text] [Related]
12. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
13. [Biocompatibility of peritoneal dialysis fluids].
Boulanger E; Moranne O; Wautier MP; Rougier JP; Ronco P; Pagniez D; Wautier JL
Nephrol Ther; 2005 Mar; 1(1):14-22. PubMed ID: 16895663
[TBL] [Abstract][Full Text] [Related]
14. First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag.
Lage C; Pischetsrieder M; Aufricht C; Jörres A; Schilling H; Passlick-Deetjen J
Perit Dial Int; 2000; 20 Suppl 5():S28-32. PubMed ID: 11229609
[TBL] [Abstract][Full Text] [Related]
15. Innovative approaches to the preservation of the peritoneal membrane: from bench to bedside.
Jörres A
Adv Ren Replace Ther; 2001 Jul; 8(3):164-72. PubMed ID: 11533917
[TBL] [Abstract][Full Text] [Related]
16. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model.
Mortier S; Faict D; Lameire NH; De Vriese AS
Kidney Int; 2005 Apr; 67(4):1559-65. PubMed ID: 15780112
[TBL] [Abstract][Full Text] [Related]
17. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions.
Topley N
Perit Dial Int; 1997; 17(1):42-7. PubMed ID: 9068021
[TBL] [Abstract][Full Text] [Related]
18. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se.
Witowski J; Bender TO; Wisniewska-Elnur J; Ksiazek K; Passlick-Deetjen J; Breborowicz A; Jörres A
Perit Dial Int; 2003; 23(4):381-90. PubMed ID: 12968847
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
20. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
